Stephanie Gill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stephanie Gill has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Elise Mann Yates
Neal Cancer Center, Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, USA
2 shared publications - Matteo Marchetti
University of Padua, Department of Gynecology and Obstetrics, Division of Women's and Children's Health, Padova, Italy
2 shared publications Pedro T. Ramirez
Neal Cancer Center, Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, USA
2 shared publications- Alexander Mathieson
Discipline of Surgery, Faculty of Medicine, Memorial University of Newfoundland, St. John’s, NL A1B 3V6, Canada
1 shared publication Allan L. Covens
University of Toronto, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Toronto, ON, Canada; Sunnybrook Health Centre, Odette Cancer Center, Division of Gynecologic Oncology, Toronto, ON, Canada
1 shared publication- Brenna E. Swift
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 18 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (7) , 104766
Feasibility and recurrence risk of sentinel lymph node biopsy in large vulvar tumors (≥4 cm)
- 18 May 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (7) , 104766
Open AccessFeasibility and recurrence risk of sentinel lymph node biopsy in large vulvar tumors (≥4 cm)
- 8 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (4) , 104552
Enhanced Recovery After Surgery (ERAS) in gynecologic surgery: hot topic debates at the 2025 ERAS World Congress
- 8 February 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (4) , 104552
Enhanced Recovery After Surgery (ERAS) in gynecologic surgery: hot topic debates at the 2025 ERAS World Congress
- 28 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102022
Indocyanine green fluorescence angiography for bowel anastomosis assessment in ovarian cancer surgery
- 28 July 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (10) , 102022
Indocyanine green fluorescence angiography for bowel anastomosis assessment in ovarian cancer surgery
- Open Access
Feasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador
Peritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is not currently provided in Newfoundland and Labrador (NL). The Canadian HIPEC Collaborative Group recommends that centres complete a minimum of one case monthly to maintain competency and achieve good outcomes. Thus, we aimed to demonstrate that the annual patient volume in NL justifies the feasibility of implementing a combined surgical and gynecological oncology CRS/HIPEC program. Methods: A retrospective chart review of the NL Cancer Care Registry identified patients with stage IV colorectal, appendiceal, or gastric cancer and stage III to IV epithelial ovarian cancer over a 1-year period (1 January 2020–31 December 2020) to identify the number of patients meeting the criteria for CRS/HIPEC and/or those referred out of province to receive the treatment. The results are presented as proportions and percentages. Results: Thirty-one patients were eligible to receive CRS/HIPEC during the study period (11 GI, 20 gynecological). Of the GI patients, 63% were referred out of province for the procedure. Gynecological patients underwent CRS and systemic therapy +/− outpatient intraperitoneal chemotherapy in NL. Conclusions: Allowing patients to receive this standard of care treatment near home reduces financial, social, and emotional stressors. Our results confirm a sufficient patient volume to support a combined CRS/HIPEC program in NL. The implementation of this program will require multidisciplinary collaboration, specialized training, equipment, and protocol development.
Open AccessFeasibility of a Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador
Peritoneal carcinomatosis is a common presentation found in advanced-stage gastrointestinal (GI) and gynecological cancers. Combined cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with significant survival benefits for select patients. CRS/HIPEC is not currently provided in Newfoundland and Labrador (NL). The Canadian HIPEC Collaborative Group recommends that centres complete a minimum of one case monthly to maintain competency and achieve good outcomes. Thus, we aimed to demonstrate that the annual patient volume in NL justifies the feasibility of implementing a combined surgical and gynecological oncology CRS/HIPEC program. Methods: A retrospective chart review of the NL Cancer Care Registry identified patients with stage IV colorectal, appendiceal, or gastric cancer and stage III to IV epithelial ovarian cancer over a 1-year period (1 January 2020–31 December 2020) to identify the number of patients meeting the criteria for CRS/HIPEC and/or those referred out of province to receive the treatment. The results are presented as proportions and percentages. Results: Thirty-one patients were eligible to receive CRS/HIPEC during the study period (11 GI, 20 gynecological). Of the GI patients, 63% were referred out of province for the procedure. Gynecological patients underwent CRS and systemic therapy +/− outpatient intraperitoneal chemotherapy in NL. Conclusions: Allowing patients to receive this standard of care treatment near home reduces financial, social, and emotional stressors. Our results confirm a sufficient patient volume to support a combined CRS/HIPEC program in NL. The implementation of this program will require multidisciplinary collaboration, specialized training, equipment, and protocol development.
- 13 April 2024
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46 (6) , 102460
Impact of COVID-19 Public Health Restrictions on the Pregnancy Experience: A Mixed-Methods Study
- 13 April 2024
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46 (6) , 102460
Impact of COVID-19 Public Health Restrictions on the Pregnancy Experience: A Mixed-Methods Study
- 8 February 2024
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 143 (4) , e125-e128
Endometrial Cancer in a Transgender Man with Prolonged Exogenous Testosterone Use
BACKGROUND: Hormone therapy (HT) in transgender males requires monitoring. For amenorrheic transmasculine individuals on HT, episodes of abnormal vaginal bleeding should be assessed promptly. CASE: A 33-year-old transgender man on exogenous testosterone therapy for medical gender transition was found to have stage IV endometrioid endometrial adenocarcinoma. Surgical resection was performed for symptom control, and the patient was treated with palliative chemotherapy. The tumor was androgen receptor–negative, and, after a multidisciplinary discussion of the risks and benefits of continuing exogenous testosterone, testosterone therapy was restarted postoperatively. CONCLUSION: Long-term androgen use may have unknown implications for the development of malignancy, and treating reproductive organ cancer in transgender males may be complicated by the desire to continue androgen therapy.
- 8 February 2024
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 143 (4) , e125-e128
Endometrial Cancer in a Transgender Man with Prolonged Exogenous Testosterone Use
BACKGROUND: Hormone therapy (HT) in transgender males requires monitoring. For amenorrheic transmasculine individuals on HT, episodes of abnormal vaginal bleeding should be assessed promptly. CASE: A 33-year-old transgender man on exogenous testosterone therapy for medical gender transition was found to have stage IV endometrioid endometrial adenocarcinoma. Surgical resection was performed for symptom control, and the patient was treated with palliative chemotherapy. The tumor was androgen receptor–negative, and, after a multidisciplinary discussion of the risks and benefits of continuing exogenous testosterone, testosterone therapy was restarted postoperatively. CONCLUSION: Long-term androgen use may have unknown implications for the development of malignancy, and treating reproductive organ cancer in transgender males may be complicated by the desire to continue androgen therapy.
- 4 July 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (7) , 960
Vulvar squamous cell carcinoma metastasizes to lung pleura
- 4 July 2022
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (7) , 960
Vulvar squamous cell carcinoma metastasizes to lung pleura